摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2,4-dichlorophenyl)-8-(3-pentyl)-7-ethyl-2-methyl-pyrazolo[1,5-a]-1,3,5-triazine

中文名称
——
中文别名
——
英文名称
4-(2,4-dichlorophenyl)-8-(3-pentyl)-7-ethyl-2-methyl-pyrazolo[1,5-a]-1,3,5-triazine
英文别名
4-(2,4-dichlorophenyl)-7-ethyl-2-methyl-8-pentan-3-ylpyrazolo[1,5-a][1,3,5]triazine
4-(2,4-dichlorophenyl)-8-(3-pentyl)-7-ethyl-2-methyl-pyrazolo[1,5-a]-1,3,5-triazine化学式
CAS
——
化学式
C19H22Cl2N4
mdl
——
分子量
377.316
InChiKey
SNMJCYLJTFHBHT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    参考文献:
    名称:
    Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-Releasing factor (CRF) receptor ligands
    摘要:
    The syntheses and rat CRF receptor binding affinities of 'retro-pyrazolotriazine' corticotropin-releasing factor (CRF) ligands 4 are reported. Some have high affinity for rat CRF receptors (K-i < 10 nM). The data provide additional support for the hypothesis that it is possible to interchange isosteric cores with similar electronic properties in the design of high-affinity CRF receptor ligands, provided the peripheral pharmacophore elements are maintained in the same three-dimensional array. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(03)00398-5
点击查看最新优质反应信息

文献信息

  • Pyrazolotriazines as CRF antagonists
    申请人:——
    公开号:US20020147338A1
    公开(公告)日:2002-10-10
    The present invention relates to pyrazolotriazines according to formula (I) 1 and stereoisomers, isomers and salts thereof wherein R 1 -R 5 are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
    本发明涉及按照公式(I)1及其立体异构体、同分异构体和盐所选择的R1-R5从特定烷基、芳基和杂环芳基物种中选择,如规范中所定义,其中所有化合物均可用作CRF拮抗剂,因此在治疗神经系统疾病以及多种其他与CRF相关的疾病或症状中有用。
  • US6960583B2
    申请人:——
    公开号:US6960583B2
    公开(公告)日:2005-11-01
  • US7026317B2
    申请人:——
    公开号:US7026317B2
    公开(公告)日:2006-04-11
  • Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-Releasing factor (CRF) receptor ligands
    作者:Paul J Gilligan、Beverly K Folmer、Richard A Hartz、Stephanie Koch、Kausik K Nanda、Stephen Andreuski、Lawrence Fitzgerald、Keith Miller、William J Marshall
    DOI:10.1016/s0968-0896(03)00398-5
    日期:2003.9
    The syntheses and rat CRF receptor binding affinities of 'retro-pyrazolotriazine' corticotropin-releasing factor (CRF) ligands 4 are reported. Some have high affinity for rat CRF receptors (K-i < 10 nM). The data provide additional support for the hypothesis that it is possible to interchange isosteric cores with similar electronic properties in the design of high-affinity CRF receptor ligands, provided the peripheral pharmacophore elements are maintained in the same three-dimensional array. (C) 2003 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

酪氨酸,2-甲氧基-O-甲基- 达美司特 百里酚-6-磺化三(2-羟基乙基)铵 吡唑并[1,5-a][1,3,5]噻嗪-4(3H)-酮 吡唑并[1,5-a][1,3,5]三嗪-2,4-二胺 吡唑并[1,5-D][1,2,4]三嗪酮 吡唑并[1,5-A]-1,3,5-三嗪-2,4(1H,3H)-二酮 N4-(1,1-二甲基乙基)-7-甲基吡唑并(1,5-a)-1,3,5-三嗪-2,4-二胺盐酸盐 N'-甲酰基-4-氨基吡唑并[5,1-c][1,2,4]三嗪-3-甲酰肼 8-苄基-2-甲基-4-(N-甲基氨基)吡唑并[1,5-a]-1,3,5-三嗪 8-溴-4-氯-2-(甲基硫代)吡唑并[1,5-a][1,3,5]三嗪 7-甲基-6H-吡唑并[4,5-e][1,2,3]三嗪-4-酮 7-甲基-1,7-二氢-4H-吡唑并[3,4-d][1,2,3]三嗪-4-酮2-氧化物 7-(叔丁基)吡唑并[1,5-a][1,3,5]三嗪-4(3H)-酮 5,6-二氢吡唑并[1,5-d][1,2,4]三嗪-4,7-二酮 4-甲氧基吡唑并[1,5-a][1,3,5]三嗪 4-氯-2-(甲硫基)吡唑并[1,5-a][1,3,5]三嗪 4-氨基-7-甲基吡唑并[5,1-C][1,2,4]三嗪-3-甲腈 4,7-二甲基吡唑并[5,1-c][1,2,4]三嗪-3-羧酸乙酯 4,7-二甲基吡唑并[5,1-C][1,2,4]三嗪-3-羧酸 4,6-二氢-6-(碘乙酰基)-3-甲基-4-亚甲基吡唑并[5,1-c][1,2,4]三嗪 3-甲氧基-2H-吡唑并[4,3-e][1,2,4]三嗪 3-(1,1-二甲基乙基)-7-(5-甲基-3-异恶唑基)-2-[(1-甲基-1H-1,2,4-三唑-5-基)甲氧基]吡唑并[1,5-d][1,2,4]三嗪 3,4-二甲基吡唑并[5,1-c][1,2,4]三嗪 2-甲基吡唑并[1,5-d][1,2,4]三嗪-4(5H)-酮 2-甲基-4-(N-甲基氨基)-8-[(2-噻吩基)甲基]吡唑并[1,5-a]-1,3,5-三嗪 2-Thi氧代-2,3-二氢吡唑并[1,5-a][1,3,5]噻嗪-4(1H)-酮 2-(甲基硫代)吡唑并[1,5-a][1,3,5]噻嗪-4(3H)-酮 2,4-二氨基-吡唑并(1,5-a)-S-三嗪盐酸盐半水合物 2,4-二(甲基氨基)-7-甲基吡唑并(1,5-a)-S-三嗪 1-(4,7-二甲基吡唑并[5,1-c][1,2,4]三氮杂-3-基)-1-乙酮 4-(2,4-dichlorophenyl)-8-(3-pentyl)-7-ethyl-2-methyl-pyrazolo[1,5-a]-1,3,5-triazine 2-(4-tert-butylphenyl)-4-({3-[(2,3-dihydro-1H-inden-2-yl)amino]-2,2-difluoropropyl}amino)-6H,7H-pyrazolo[1,5-a][1,3,5]triazin-7-one 2-(4-tert-butylphenyl)-4-{[3-(dimethylamino)propyl]amino}-8-[(6-methylpyridin-3-yl)methyl]-6H,7H-pyrazolo[1,5-a][1,3,5]triazin-7-one 4-methyl-N-(1-methyl-1-phenylethyl)-2-phenyl-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine-8-carboxamide 2,4-diphenyl-pyrazolo[1,5-a][1,3,5]triazine 3H-8-carbonitrile-2-(5-chlorouracil-6-methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)-7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)-7-methylpyrazolo[1,5-a][1,3,5]triazin-4-one 3H-8-carboxylic acid ethyl ester 2-(5-chlorouracil-6-methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)-7-trifluoromethylpyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)-8-methylpyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-one 3H-2-(5-chlorouracil-6-methylthio)-8-iodopyrazolo[1,5-a][1,3,5]triazin-4-one 3H-8-chloro-2-(5-chlorouracil-6-methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-one 3H-8-bromo-2-(5-chlorouracil-6-methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-one 6-[4-(1-hydroxy-1-methylethyl)phenyl]-2-methyl-5H-1,5,7,7a-tetraazainden-4-one Pyrazolo<3,2-f><1,2,4>triazin-4(3H)-on methyl 3,7-dimethyl-4-oxo-4,6-dihydro-pyrazolo[5,1-c][1,2,4]triazine-8-carboxylate 2-(4-tert-butylphenyl)-4-{[3-(4-chloro-3-methylphenoxy)propyl]sulfanyl}-6H,7H-pyrazolo[1,5-a] [1,3,5]triazin-7-one